Slingshot members are tracking this event:
New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients who had relapsed or progressed after auto-HSCT and subsequent brentuximab vedotin, as assessed by an independent radiologic review committee
Slingshot Insights Explained
Jun 10, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Nivolumab, Opdivo, Hodgkin Lymphoma, Brentuximab Vedotin